Literature DB >> 2943952

Modulation of the effects of fluoropyrimidines on toxicity and tumor inhibition in rodents by uridine and thymidine.

H R Hartmann, W Bollag.   

Abstract

Uridine and/or thymidine were administered concomitantly with 5-fluorouracil (5-FU) and 5'-deoxy-5-fluorouridine (5'-dFUR) to mice and rats in order to establish whether the physiological nucleosides acting in vitro as antagonists can diminish fluoropyrimidine toxicity in vivo. In addition, the influence of orally co-administered uridine on antitumor activity of 5-FU and 5'-dFUR in mice has been studied. All co-administrations aggravated the general toxicity of both fluoropyrimidines. Tumor inhibition was enhanced by uridine, but the therapeutic ratio was not improved compared to monotherapy with either 5-FU or 5'-dFUR.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2943952     DOI: 10.1007/bf02934563

Source DB:  PubMed          Journal:  Med Oncol Tumor Pharmacother        ISSN: 0736-0118


  21 in total

1.  Familial pyrimidinemia and pyrimidinuria associated with severe fluorouracil toxicity.

Authors:  M Tuchman; J S Stoeckeler; D T Kiang; R F O'Dea; M L Ramnaraine; B L Mirkin
Journal:  N Engl J Med       Date:  1985-07-25       Impact factor: 91.245

2.  Potentiation of the anti-tumor activity of 5FU by thymidine and its correlation with the formation of (5FU)RNA.

Authors:  S Spiegelman; R Nayak; R Sawyer; R Stolfi; D Martin
Journal:  Cancer       Date:  1980-03-15       Impact factor: 6.860

3.  Modulation of 5-FU action by thymidine in murine and human tumors.

Authors:  C W Young; T M Woodcock; D S Martin
Journal:  Cancer Treat Rep       Date:  1981

4.  Effects of uridine and thymidine on the degradation of 5-fluorouracil, uracil, and thymine by rat liver dihydropyrimidine dehydrogenase.

Authors:  M Tuchman; M L Ramnaraine; R F O'Dea
Journal:  Cancer Res       Date:  1985-11       Impact factor: 12.701

5.  Uridine rescue from the lethal toxicity of 5-fluorouracil in mice.

Authors:  P Klubes; I Cerna; M A Meldon
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

6.  Combination clinical trials with thymidine and fluorouracil: a phase I and clinical pharmacologic evaluation.

Authors:  T M Woodcock; D S Martin; L A Damin; N E Kemeny; C W Young
Journal:  Cancer       Date:  1980-03-15       Impact factor: 6.860

7.  High-dose 5-fluorouracil with delayed uridine "rescue" in mice.

Authors:  D S Martin; R L Stolfi; R C Sawyer; S Spiegelman; C W Young
Journal:  Cancer Res       Date:  1982-10       Impact factor: 12.701

8.  [5'-deoxy-5-fluoruridine, a new antineoplastic pyrimidine antimetabolite].

Authors:  H R Hartmann; W Bollag
Journal:  Schweiz Med Wochenschr       Date:  1980-07-08

9.  Comparison of pharmacokinetics of 5-fluorouracil and 5-fluorouracil with concurrent thymidine infusions in a Phase I trial.

Authors:  J M Kirkwood; W Ensminger; A Rosowsky; N Papathanasopoulos; E Frei
Journal:  Cancer Res       Date:  1980-01       Impact factor: 12.701

10.  Phase I and pharmacokinetic studies of high-dose uridine intended for rescue from 5-fluorouracil toxicity.

Authors:  A Leyva; C J van Groeningen; I Kraal; H Gall; G J Peters; J Lankelma; H M Pinedo
Journal:  Cancer Res       Date:  1984-12       Impact factor: 12.701

View more
  3 in total

1.  Effect of uridine coadministration on 5'-deoxy-5-fluorouridine disposition in rats.

Authors:  J L Au; M G Wientjes; S L Bramer
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

2.  Use of oral uridine as a substitute for parenteral uridine rescue of 5-fluorouracil therapy, with and without the uridine phosphorylase inhibitor 5-benzylacyclouridine.

Authors:  D S Martin; R L Stolfi; R C Sawyer
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

3.  Effect of coadministered uridine on intestinal first-pass metabolism of 5'-deoxy-5-fluorouridine in conscious rats--an evaluation by method of portal-systemic concentration difference.

Authors:  Y Sawai; K Yamaoka; T Nakagawa
Journal:  Pharm Res       Date:  1998-07       Impact factor: 4.200

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.